Three subsidiaries of Boston Scientific—Guidant Corporation, Cardiac Pacemakers and Guidant Sales—which are known as Boston Scientific Cardiac Rhythm Management, have reached an agreement with the attorneys general of 35 states and the District of Columbia to settle investigations associated with Guidant Corporation's Ventak Prizm 2DR Model 1861, Contak Renewal Model H135 and Contak Renewal 2 Model H155 devices.

Under the terms of the agreement, the three subsidiaries will pay a sum total of $16.75 million, but will not admit any liability.

The Natick, Mass.-based company said it also agreed to extend its Supplemental Warranty Program for these devices an additional six months and to reaffirm its commitment for implemental change recommended by the independent panel commissioned by Guidant in 2005, including having a patient safety officer and a patient safety advisory board.